Englander Institute for Precision Medicine
Found 811 results
Author Title Type [ Year(Desc)]
Filters: Corrigendum-whole-genome-and-transcriptome-analysis-pancreatic-acinar-cell-carcinoma is   [Clear All Filters]
2025
Teng M, Guo J, Xu X, Ci X, Mo Y, Kohen Y, Ni Z, Chen S, Guo WYuan, Bakht M et al..  2025.  Circular RMST cooperates with lineage-driving transcription factors to govern neuroendocrine transdifferentiation.. Cancer Cell.
Kadri S, Craven KE, Fussell AM, Gee EPS, Jordan D, Klee EW, Krumm N, Temple-Smolkin RL, Zehir A, Zhang W et al..  2025.  Clinical Bioinformatician Body of Knowledge-Bioinformatics and Software Core: A Report of the Association for Molecular Pathology.. J Mol Diagn.
Agarwal PK, Sternberg CN.  2025.  Clinical trials corner issue 11(1).. Bladder Cancer. 11(1):23523735241309418.
Nauseef JT, Chu TR, Hooper WF, Alonso A, Oku A, Geiger H, Goldstein ZR, Shah M, Sigouros M, Manohar J et al..  2025.  A complex phylogeny of lineage plasticity in metastatic castration resistant prostate cancer.. NPJ Precis Oncol. 9(1):91.
Müller-Dott S, Jaehnig EJ, Munchic KPham, Jiang W, Yaron-Barir TM, Savage SR, Garrido-Rodriguez M, Johnson JL, Lussana A, Petsalaki E et al..  2025.  Comprehensive evaluation of phosphoproteomic-based kinase activity inference.. Nat Commun. 16(1):4771.
Neth BJ, Huynh K, Giles C, Wang T, Mellett NA, Duong T, Blach C, Schimmel L, Register TC, Blennow K et al..  2025.  Consuming a modified Mediterranean ketogenic diet reverses the peripheral lipid signature of Alzheimer's disease in humans.. Commun Med (Lond). 5(1):11.
Chew SMei, Teumer A, Matías-García PR, Gieger C, Winckelmann J, Suhre K, Herder C, Rathmann W, Peters A, Waldenberger M.  2025.  Cross-sectional and longitudinal association of seven DNAm-based predictors with metabolic syndrome and type 2 diabetes.. Clin Epigenetics. 17(1):58.
Jiang W, Jaehnig EJ, Liao Y, Shi Z, Yaron-Barir TM, Johnson JL, Cantley LC, Zhang B.  2025.  Deciphering the dark cancer phosphoproteome using machine-learned co-regulation of phosphosites.. Nat Commun. 16(1):2766.
Kim YE, Dobko M, Li H, Shao T, Periyakoil P, Tipton C, Colasacco C, Serpedin A, Elemento O, Sabuncu M et al..  2025.  A Deep-Learning Model for Multi-class Audio Classification of Vocal Fold Pathologies in Office Stroboscopy.. Laryngoscope.
Wong EWP, Sahin M, Yang R, Lee UJ, Li D, Zhan YA, Misra R, Tomas F, Alomran N, Polyzos A et al..  2025.  Disruption of TAD hierarchy promotes LTR co-option in cancer.. Nat Genet.
Sternberg CN, Hussain M.  2025.  Does circulating DNA tumor fraction add value to prostate-specific antigen in metastatic castration-resistant prostate cancer? Transl Cancer Res. 14(5):2536-2538.
Tian Y, Bhattacharya R, Yoo S, Jiang F, Park E, Granados GLara, Shen Y, Park K-S, Kaniskan HUmit, Jin J et al..  2025.  Epigenomic analysis identifies DTP subpopulation using HOPX to develop targeted therapy resistance in lung adenocarcinoma.. iScience. 28(5):112387.
Cheng APellan, Widman AJ, Arora A, Rusinek I, Sossin A, Rajagopalan S, Midler N, Hooper WF, Murray RM, Halmos D et al..  2025.  Error-corrected flow-based sequencing at whole-genome scale and its application to circulating cell-free DNA profiling.. Nat Methods.
de Bono JS, He M, Shi Z, Nowicka M, Bracarda S, Sternberg CN, Chi KN, Olmos D, Sandhu S, Massard C et al..  2025.  Final Overall Survival and Molecular Data Associated with Clinical Outcomes in Patients Receiving Ipatasertib and Abiraterone in the Phase 3 IPATential150 Trial.. Eur Urol.
Claridge SE, Nath S, Baum A, Farias R, Cavallo J-A, Rizvi NM, De Boni L, Park E, Granados GLara, Hauesgen M et al..  2025.  Functional genomics pipeline identifies CRL4 inhibition for the treatment of ovarian cancer.. Clin Transl Med. 15(2):e70078.
Borea R, Reduzzi C.  2025.  The growing field of liquid biopsy and its Snowball effect on reshaping cancer management.. J Liq Biopsy. 8:100293.
Mizuno K, Ku S-Y, Venkadakrishnan VBalaji, Bakht MK, Sigouros M, Chan J, Trigos A, Driskill JH, Manohar J, King A et al..  2025.  Intraindividual epigenetic heterogeneity underlying phenotypic subtypes of advanced prostate cancer.. Nat Commun. 16(1):5543.
Barton BM, Son F, Verma A, Bal SKumar, Tang Q, Wang R, Umphred-Wilson K, Khan R, Trichka J, Dong H et al..  2025.  IRE1α-XBP1 safeguards hematopoietic stem and progenitor cells by restricting pro-leukemogenic gene programs.. Nat Immunol.
Rowdo FPMadorsky, Martini R, Ackermann SE, Tang CP, Tranquille M, Irizarry A, Us I, Alawa O, Moyer JE, Sigouros M et al..  2025.  Kinome-Focused CRISPR-Cas9 Screens in African Ancestry Patient-Derived Breast Cancer Organoids Identify Essential Kinases and Synergy of EGFR and FGFR1 Inhibition.. Cancer Res. 85(3):551-566.
Howlader MJ, Rashighi M, Santambrogio L, Lu TT.  2025.  Lymphatic messengers: Non-antigen soluble mediators from diseased tissues to draining lymph nodes.. Curr Opin Immunol. 93:102536.
Guevara D, Shin N, Boiko A, Valiev I, Elsaeed AG, Mosquera JMiguel, Assaad MAl, Manohar J, Sigouros M, Zaichikova A et al..  2025.  Mesonephric Adenocarcinoma in a Young Male Patient.. Anticancer Res. 45(2):619-623.
Tyrakis PA, Kampjut D, Steele GF, H Lindström JG, Chirnomas D, Hopkins BD, Goncalves MD, Mukherjee S, Cantley LC, Maddocks ODK.  2025.  Multi-node inhibition targeting mTORC1, mTORC2 and PI3Kα potently inhibits the PI3K/AKT/mTOR pathway in endometrial and breast cancer models.. Br J Cancer.
Fiore D, Cappelli LVincenzo, Zhaoqi L, Kotlov N, Sorokina M, Phillip J, Zumbo P, Yoffe L, Ghione P, Wang A et al..  2025.  A patient-derived T cell lymphoma biorepository uncovers pathogenetic mechanisms and host-related therapeutic vulnerabilities.. Cell Rep Med. :102029.
Horne CR, Dite TA, Young SN, Mather LJ, Dagley LF, Johnson JL, Yaron-Barir TM, Huntsman EM, Daly LA, Byrne DP et al..  2025.  "PSKH1 kinase activity is differentially modulated via allosteric binding of Ca²⁺ sensor proteins". Proc Natl Acad Sci U S A. 122(8):e2420961122.
Laurent P-A, Andre F, Bobard A, Deandreis D, Demaria S, Depil S, Eichmüller SB, Fernandez-Palomo C, Foijer F, Galluzzi L et al..  2025.  Pushing the boundaries of radiotherapy-immunotherapy combinations: highlights from the 7th immunorad conference.. Oncoimmunology. 14(1):2432726.